Immatics Announces Third Quarter 2022 Financial Results and Business Update
17 nov. 2022 07h00 HE | https://immatics.com/
Interim clinical update on ACTengine® IMA203 TCR-T monotherapy targeting PRAME demonstrated high confirmed objective response rate (cORR) of 50% (6/12) at or above target dose across Phase 1a and...
Immatics veröffentlicht Ergebnisse des dritten Quartals 2022 sowie ein Update zur Geschäftsentwicklung
17 nov. 2022 07h00 HE | Immatics N.V.
Klinisches Daten-Update zu ACTengine® IMA203 TCR-T-Monotherapie gegen die Zielstruktur PRAME zeigt hohe bestätigte objektive Ansprechrate (confirmed objective response rate, cORR) von 50 % (6/12) bei...
EVAXION_BLACK_RGB.jpg
Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02
17 nov. 2022 06h59 HE | Evaxion Biotech
COPENHAGEN, Denmark, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
TIP_link_300x300.jpg
$32.4 Bn Cell Therapy Instruments Market to Exhibit CAGR of 13.2% by 2027, Deep Dive Analysis of Key Players and Growth Opportunities
15 nov. 2022 08h17 HE | The Insight Partners
New York, Nov. 15, 2022 (GLOBE NEWSWIRE) -- According to The Insight Partners latest study on "Cell Therapy Instrument Market Size, Share, Growth, Trends and Forecast to 2027 – COVID-19 Impact and...
SmallCapVoice BCTX 111422 IG (2)
BriaCell CEO Discusses Positive Clinical Results of its Breast Cancer Immunotherapy Treatment in an Audio Interview with SmallCapVoice.com
15 nov. 2022 08h00 HE | Briacell Therapeutics Corp.
AUSTIN, Texas, Nov. 15, 2022 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new audio interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp....
ImmunOs Therapeutics´ Lead Program Shows Strong Anti-Tumor Activity In Vivo and In Vitro
15 nov. 2022 04h00 HE | AKAMPION
- Promising data presented at Protein and Antibody Engineering Summit (PEGS) - Multi-functional agent targeting three immune checkpoint receptors  - Potential as mono- and combination therapy for...
Global Cancer Gene Therapy Market
Cancer Gene Therapy Market Report 2022: High Growth in the Pharmaceutical Industry Driving Sector
14 nov. 2022 08h21 HE | Research and Markets
Dublin, Nov. 14, 2022 (GLOBE NEWSWIRE) -- The "Cancer Gene Therapy Market Size, Share & Trends Analysis Report by Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer), by...
PDS Biotech Logo.png
PDS Biotech Reports Third Quarter 2022 Financial Results and Provides Business Update
14 nov. 2022 07h30 HE | PDS Biotechnology Corporation
Announced preliminary PDS0101 efficacy and safety data for Phase 2 clinical studies led by The University of Texas MD Anderson Cancer Center (IMMUNOCERV) and The National Cancer Institute at SITC...
PDS Biotech Logo.png
PDS Biotech Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from IMMUNOCERV Phase 2 Clinical Trial
14 nov. 2022 07h00 HE | PDS Biotechnology Corporation
In the trial studying the combination of PDS0101 with standard-of-care chemoradiotherapy: 100% (9/9) showed clinical response (>60% tumor shrinkage at mid-point evaluation)89% (8/9) had no...
BiondVax LOGO.png
BiondVax Announces Plan to Implement ADS Ratio Change
10 nov. 2022 16h00 HE | BiondVax Pharmaceuticals Ltd.
JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and...